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Heart failure (HF) affects 1–2% of the population in developed countries 
and absorbs a significant amount of human and economic resources.1,2 
HF is a complex syndrome characterised by a spectrum of symptoms 
and phenotypes: HF with preserved ejection fraction, HF with mid-
range ejection fraction and HF with reduced ejection fraction (HFrEF).3 
Differentiating patients according to left ventricular ejection fraction 
(LVEF) is relevant as these syndromes have distinct patterns of underlying 
aetiologies, demographics, comorbidities and response to therapies.4,5
The renin–angiotensin–aldosterone system (RAAS) plays a crucial 
role in HFrEF (Figure 1). Its activation has harmful long-term effects, 
such as water and salt retention, and promotes adverse ventricular 
remodelling.6 RAAS inhibitors (RAASi) are a group of drugs that 
act by antagonising the RAAS and include angiotensin-converting 
enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) and 
mineralocorticoid receptor antagonists (MRAs). Therapies that target 
the RAAS have been shown to reduce both morbidity and mortality in 
HFrEF patients.7
Renin–Angiotensin–Aldosterone System 
Inhibition in Heart Failure With Reduced 
Ejection Fraction
According to the latest European Society of Cardiology (ESC) HF 
guidelines, RAASi are recommended in all symptomatic (New York Heart 
Association class II–IV) patients with HFrEF.3 ACEi are recommended 
as first-line treatment in all HFrEF symptomatic patients, unless 
contraindicated or not tolerated, to reduce mortality and morbidity. 
Clinical trials provide strong evidence of prognostic benefits for 
combination therapy with ACEi and beta-blockers in the treatment 
of HFrEF. In particular, an ACEi is recommended in addition to a beta-
blocker for symptomatic patients with HFrEF to reduce the risk of HF 
hospitalisation and death. ACEi are also recommended in patients with 
asymptomatic left ventricular systolic dysfunction to reduce the risk of 
HF development, HF hospitalisation and death.
If ACEi are not tolerated, an ARB is recommended as second-
line treatment in symptomatic HFrEF patients.3 With the same 
aim – to reduce the risk of HF hospitalisation and death – an MRA 
is recommended for patients with HFrEF who remain symptomatic 
despite treatment with an ACEi and a beta-blocker.8 An ARB may be 
considered in patients who remain symptomatic despite treatment 
with a beta-blocker and who are unable to tolerate an MRA.3
Finally, angiotensin receptor-neprilysin inhibitors (ARNis) – a new class 
of agent acting on the RAAS and neutral endopeptidase system – 
have been developed. Among these, LCZ696 combines the moieties 
of an ARB (valsartan) and a neprilysin inhibitor (sacubitril) and has 
been found to reduce mortality and several other endpoints in HFrEF.3 
Of note, a secondary analysis of the baseline characteristics and 
treatment of patients in the Prospective comparison of ARNI with ACEI 
to Determine Impact on Global Mortality and morbidity in Heart Failure 
trial (PARADIGM-HF) showed that hyperkalemia was reduced in patients 
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treated with sacubitril/valsartan compared with enalapril.9 However, the 
long-term safety of sacubitril/valsartan still needs to be investigated.
Uptitration of Renin–Angiotensin–Aldosterone 
System Inhibitors and Hyperkalemia
A systematic review and meta-analysis compared higher versus lower 
doses of ACEi and ARBs in HFrEF.10 The results suggest that higher 
doses of ACEi and ARBs reduce the risk of HF worsening compared 
with lower doses. Higher doses also increase the likelihood of adverse 
effects compared with lower doses. Uptitration should occur in a 
gradual manner, starting from low doses – preferably in a controlled 
setting – to avoid side-effects, as recommended by the ESC guidelines.3 
As for ACEi, results from the Assessment of Treatment with Lisinopril 
and Survival (ATLAS) trial showed that HFrEF patients taking high-dose 
lisinopril had a significant reduction in risk of death or hospitalisation 
for any cause and fewer hospitalisations for HF than the low-dose 
group.11 Thus, uptitration of a RAASi to the maximum tolerated dose 
to achieve adequate inhibition of the RAAS is pivotal in improving 
outcomes in HFrEF.7
Similarly, the Heart failure Endpoint evaluation of Angiotensin II Antagonist 
Losartan (HEAAL) study showed that the ARB losartan at high dose 
significantly reduced the rate of death or admission for HF and reduced 
LVEF, compared with low-dose losartan.12 All these findings indicate the 
value of uptitrating RAASi doses to confer clinical benefit.
Unfortunately, uptitration of RAASi is associated with an increased 
risk of hyperkalemia. For this reason, RAASi are frequently omitted 
or discontinued in clinical practice. In particular, data from the ESC 
HF registry reveal that RAASi were frequently underdosed because 
of persistent and consistent hyperkalemia and/or worsening renal 
function.13 Hyperkalemia is more often observed when RAASi are 
administered in combination than when administered individually.14 Of 
note, a substantial proportion of patients receiving RAASi therapy have 
their therapy downtitrated or, more often, discontinued even after a 
single episode of elevated potassium level.7 In a retrospective study, 
RAASi discontinuation was observed in up to 25% of patients and 
underdosing of RAASi in about two-thirds of patients.15
Thus, despite their well-known efficacy, most patients receive 
submaximal doses of RAASi in clinical practice.16,17 RAASi-induced 
hyperkalemia hinders the use of these drugs, countering their 
survival benefits.7,13,14 Analyses from Swedish and Danish registries 
found that hyperkalemia was associated with increased mortality.18,19 
Interestingly, increased risks of mortality are similar for patients who 
received reduced RAASi doses and those who discontinued.20 As such, 
hyperkalemia is a crucial limitation to fully titrating RAASi, with harmful 
consequences such as increased risk of worsening HF and mortality. 
Management of Hyperkalemia and 
Implementation of Renin–Angiotensin–
Aldosterone System Inhibitors Dosage
To avoid these severe outcomes, treatment for lowering potassium 
levels may be initiated.7 Treatment should be personalised according to 
the severity of hyperkalemia and other factors such as comorbidities, 
age and levels of RAASi. According to the ESC expert consensus 
document, when hyperkalemia develops, it is recommended that 
patients’ potassium level is lowered to enable them to continue their 
RAASi therapy.7 The ESC guidelines recommend that if a withdrawal of 
these drugs is necessary, this should be a short-term cessation only 
and RAASi should be cautiously re-established as soon as possible 
while monitoring potassium levels.3 Also, potassium elevations below 
5 mmol/l should not lead to RAASi cessation because only an increase 
above 5.5 mmol/l is harmful.3,21 In this case, only temporary dose 
reduction should be considered.7
Dose reduction or discontinuation of RAASi is not always needed. 
Hyperkalemia should be considered as an expected adverse event of 
RAASi.20 Potassium levels quickly rise after induction of RAASi, but the 
risk of hyperkalemia is low if potassium level is properly monitored. 
For this reason, when starting an ACEi or an ARB, close monitoring of 
potassium, blood pressure and creatinine is recommended.3 Of note, 
the combination of ACEi or ARBs and MRAs with thiazide diuretics may 
neutralise the risks of hyperkalemia.7
However, prevention of hyperkalemia remains a controversial issue. 
Potassium monitoring should be tailored to the individual patient. 
Patients at high risk of hyperkalemia should undergo potassium 
measurements initially, at 2 weeks, 1 month and every 3 months 
thereafter. Patients at low risk of hyperkalemia should undergo testing 
at 1, 3 and 6 months after the initial event and twice yearly thereafter. 
In any case, potassium should be measured whenever there is a 
clinical indication and/or change in medications. 
Unfortunately, it has been shown that measurements of potassium are 
not regularly executed in practice.20,22 Quality-improvement programmes 
are strongly needed to improve rates of laboratory monitoring for patients 
initiated on RAASi therapy, particularly in high-risk patients.7 RAASi 
discontinuation and restarting should be planned following an algorithm, 
as in the Eplerenone in Mild Patients Hospitalization and Survival Study in 
Heart Failure (EMPHASIS-HF).23 In the near future, new potassium binders 
may help optimise RAASi therapy by allowing uptitration of RAASi dosage.
Conclusion
New therapeutic options exist to enhance potassium excretion, such as 
patiromer and sodium zirconium cyclosilicate (ZS-9), which have been 
RAASi downtitration or withdrawal lead to worsening of HF and increased risk of mortality. 
Management of hyperkalemia improves outcomes in HFrEF. HF = heart failure; HFrEF = heart 
failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist;  
RAAS = renin–angiotensin–aldosterone system; RAASi = renin–angiotensin–aldosterone 
system inhibitors.
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Figure 1: Role of Renin–Angiotensin–Aldosterone System 
and its Inhibitors in Heart Failure with Reduced Ejection 
Fraction
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shown in randomised trials to significantly reduce serum potassium in 
patients with hyperkalemia on RAASi. Clinical studies of patiromer and ZS-9 
demonstrated their dose-dependent potassium-lowering effects. These 
new potassium binders may be helpful in optimising RAASi therapies 
in patients with hyperkalemia or at increased risk of developing it.7 
However, the safety and long-term benefits for outcomes and drug–drug 
interactions, should be further evaluated in proper clinical trials.
Future studies should consider the inclusion of patients with RAASi-
induced hyperkalemia – who are usually excluded from clinical trials 
– to overcome the knowledge gap in this important subgroup.24 Further 
studies of uptitration to optimal dosing of RAASi in HF are also needed. 
Future research should focus on prevention of hyperkalemia and 
strategies to optimise RAASi.
Beyond hyperkalemia, it should be noted that submaximal dosing 
of RAASi may be caused by other factors, such as symptomatic 
hypotension, syncope, hypoperfusion and reduced kidney function. 
In particular, hypotension and worsening renal function are common 
barriers to the treatment of HFrEF. Thus, correcting hyperkalemia 
often does not resolve the problem and management of these side-
effects is needed. 
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